Reduces elevated intraocular pressure (IOP). ANDA 214687, held by Alembic. Travoprost.
As of Nov 16, 2026, ANDA 214687 (Travoprost), held by Alembic, was first approved by FDA on Dec 17, 2025, with 0 approved supplements and 0 published complete response letters.
Travoprost ophthalmic solution, 0.004% (ionic buffered solution) is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 17, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Travoprost0.004% · solution/drops;ophthalmic | Travoprost | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters